Home › Compare › EELFF vs ABBV

EELFF vs ABBV: Dividend Comparison 2026

EELFF yields 142857.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EELFF wins by $1.703105290929614e+28M in total portfolio value
10 years
EELFF
EELFF
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full EELFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EELFF vs ABBV

📍 EELFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEELFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EELFF + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EELFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EELFF
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EELFF beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EELFF + ABBV for your $10,000?

EELFF: 50%ABBV: 50%
100% ABBV50/50100% EELFF
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EELFF
No analyst data
Altman Z
3.7
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EELFF buys
0
ABBV buys
0
No recent congressional trades found for EELFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEELFFABBV
Forward yield142857.14% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$1.703105290929614e+28M$102.3K ✓
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$1.70295189426983e+28M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EELFF vs ABBV ($10,000, DRIP)

YearEELFF PortfolioEELFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,296,414$14,285,714.29$11,550$430.00+$14.28M → EELFF
2$19,102,632,658$19,087,335,494.95$13,472$627.96+$19102.62M → EELFF
3$23,856,124,353,624$23,835,684,536,679.88$15,906$926.08+$23856124.34M → EELFF
4$27,845,102,711,212,050$27,819,576,658,153,670.00$19,071$1,382.55+$27845102711.19M → EELFF
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$23,302$2,095.81+$30376787884694.16M → EELFF
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$29,150$3,237.93+$30972831647170752.00M → EELFF
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$37,536$5,121.41+$29516720240819920896.00M → EELFF
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$50,079$8,338.38+$2.6290911335300947e+22M → EELFF
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$69,753$14,065.80+$2.1887488081496375e+25M → EELFF
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$102,337$24,771.77+$1.703105290929614e+28M → EELFF

EELFF vs ABBV: Complete Analysis 2026

EELFF — Stock

Barys Resources Ltd. engages in the business of uranium, copper, and base metals exploration. Its properties include Agadez Uranium, Ghanzi West Copper-Silver, Tarouadji Lithium-Tin, and Virgo Copper projects. The company was founded on February 9, 2011 and is headquartered in West Perth, Australia.

Full EELFF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EELFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EELFF vs SCHDEELFF vs JEPIEELFF vs OEELFF vs KOEELFF vs MAINEELFF vs JNJEELFF vs MRKEELFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.